Lateo.net - Flux RSS en pagaille (pour en ajouter : @ moi)

🔒
❌ À propos de FreshRSS
Il y a de nouveaux articles disponibles, cliquez pour rafraîchir la page.
À partir d’avant-hierArs Technica

Experimental antibiotic kills deadly superbug, opens whole new class of drugs

Par : Beth Mole
This digitally colorized scanning electron microscopic (SEM) depicts a number of clusters of aerobic, Gram-negative, non-motile, Acinetobacter baumannii bacteria, under a relatively low magnification of 1,546X

Enlarge / This digitally colorized scanning electron microscopic (SEM) depicts a number of clusters of aerobic, Gram-negative, non-motile, Acinetobacter baumannii bacteria, under a relatively low magnification of 1,546X

A new experimental antibiotic can handily knock off one of the world's most notoriously drug-resistant and deadly bacteria —in lab dishes and mice, at least. It does so with a never-before-seen method, cracking open an entirely new class of drugs that could yield more desperately needed new therapies for fighting drug-resistant infections.

The findings appeared this week in a pair of papers published in Nature, which lay out the extensive drug development work conducted by researchers at Harvard University and the Swiss-based pharmaceutical company Roche.

In an accompanying commentary, chemists Morgan Gugger and Paul Hergenrother of the University of Illinois at Urbana-Champaign discussed the findings with optimism, noting that it has been more than 50 years since the Food and Drug Administration has approved a new class of antibiotics against the category of bacteria the drug targets: Gram-negative bacteria. This category—which includes gut pathogens such as E. coli, Salmonella, Shigella, and the bacteria that cause chlamydia, the bubonic plague, gonorrhea, whooping cough, cholera, and typhoid, to name a few—is extraordinarily challenging to kill because it's defined by having a complex membrane structure that blocks most drugs, and it's good at accumulating other drug-resistance strategies

Read 13 remaining paragraphs | Comments

Probiotic bacterium kills preterm infant; FDA blasts supplement maker

Par : Beth Mole
A premature baby in the neonatal intensive care unit at University of Iowa Stead Family Children's Hospital in Iowa City, Iowa on August 13, 2021. The baby was born two days earlier at 22 weeks and at birth weighed just 1 lb., 0.1 oz.

Enlarge / A premature baby in the neonatal intensive care unit at University of Iowa Stead Family Children's Hospital in Iowa City, Iowa on August 13, 2021. The baby was born two days earlier at 22 weeks and at birth weighed just 1 lb., 0.1 oz. (credit: Getty | Michael S. Williamson/The Washington Post)

The Food and Drug Administration is warning health care providers not to use probiotics containing live bacteria or yeast in preterm infants after the agency began investigating the July death of a preterm, low-weight infant given such a product in an unnamed hospital.

The infant developed sepsis from the bacterium in the probiotic product—Evivo with MCT Oil made by Infinant Health—and subsequently died.

In a statement to Ars, the FDA said it quickly investigated the death after receiving an initial report on July 31. "Infant deaths are especially tragic and determining causality of preterm infant death can be particularly complicated," an agency spokesperson said. The agency reviewed medical records and laboratory tests from the case and collected clinical samples and product samples for analysis.

Read 17 remaining paragraphs | Comments

❌